AR072102A1 - Derivados de 2-oxo-alquil-1-piperazin-2-ona, su preparacion, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por los receptores p75ntr. - Google Patents

Derivados de 2-oxo-alquil-1-piperazin-2-ona, su preparacion, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por los receptores p75ntr.

Info

Publication number
AR072102A1
AR072102A1 ARP090102109A ARP090102109A AR072102A1 AR 072102 A1 AR072102 A1 AR 072102A1 AR P090102109 A ARP090102109 A AR P090102109A AR P090102109 A ARP090102109 A AR P090102109A AR 072102 A1 AR072102 A1 AR 072102A1
Authority
AR
Argentina
Prior art keywords
piperazin
oxo
group
alkyl
derivatives
Prior art date
Application number
ARP090102109A
Other languages
English (en)
Inventor
Marco Baroni
Francoise Bono
Sandrine Delbary-Gossart
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR072102A1 publication Critical patent/AR072102A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Derivados de 4-{2-[fenil-3,6-dihidro-piridin-1-il]-2-oxo-alquil}-1-piperazin-2-ona y 4-{2-[fenil-2,5-dihidro-pirrol-1-il]-2-oxo-alquil}-1-piperazin-2-ona. Su preparacion y su aplicacion en terapeutica, en el tratamiento de enfermedades mediadas por los receptores P75NTR. Se provee adem s una composicion farmaceutica que los comprende. Reivindicacion 1: Compuesto de formula (1) en la que m representa 0 o 1; A representa formula (2) y B representa un  tomo de hidrogeno o A representa un  tomo de hidrogeno y B representa formula (2); R1 y R2, identicos o diferentes, representan independientemente un  tomo de hidrogeno o de halogeno, un grupo alquilo C1-4, fluoroalquilo C1-4, perfluoroalquilo C1-2, alcoxi C1-4 o un grupo trifluorometoxi; n es 1 o 2; R3 representa un grupo e formulas (3) donde R4 y R5, identicos o diferentes, se situan sobre cualquier posicion disponible, y representan independientemente un  tomo de hidrogeno o de halogeno, hidroxilo, un grupo alquilo C1-4, fluoroalquilo C1-4, perfluoroalquilo C1-2, alcoxi C1-4, un grupo trifluorometoxi, un ciano, un grupo COOH, COOalquilo, CONH2, CONR6R7 o NHCOR; R, R6 y R7 representan un alquilo C1-6; en forma de base o de sales de adicion de  cido.
ARP090102109A 2008-06-13 2009-06-11 Derivados de 2-oxo-alquil-1-piperazin-2-ona, su preparacion, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por los receptores p75ntr. AR072102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0803298A FR2932481B1 (fr) 2008-06-13 2008-06-13 Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
AR072102A1 true AR072102A1 (es) 2010-08-04

Family

ID=40305319

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102109A AR072102A1 (es) 2008-06-13 2009-06-11 Derivados de 2-oxo-alquil-1-piperazin-2-ona, su preparacion, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por los receptores p75ntr.

Country Status (32)

Country Link
US (2) US8247404B2 (es)
EP (1) EP2310383B8 (es)
JP (1) JP5476372B2 (es)
KR (1) KR101601999B1 (es)
CN (1) CN102124001B (es)
AR (1) AR072102A1 (es)
AT (1) ATE535524T1 (es)
AU (1) AU2009259120B2 (es)
BR (1) BRPI0915482B8 (es)
CA (1) CA2726666C (es)
CL (1) CL2010001432A1 (es)
CO (1) CO6300943A2 (es)
CY (1) CY1112417T1 (es)
DK (1) DK2310383T3 (es)
EA (1) EA019924B1 (es)
ES (1) ES2378380T3 (es)
FR (1) FR2932481B1 (es)
HK (1) HK1158632A1 (es)
HR (1) HRP20120187T1 (es)
IL (1) IL209903A (es)
JO (1) JO2773B1 (es)
MX (1) MX2010013694A (es)
MY (1) MY151228A (es)
NZ (1) NZ589842A (es)
PL (1) PL2310383T3 (es)
PT (1) PT2310383E (es)
RS (1) RS52252B (es)
SI (1) SI2310383T1 (es)
TW (1) TWI400238B (es)
UY (1) UY31894A (es)
WO (1) WO2009150387A1 (es)
ZA (1) ZA201008791B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
ES2699410T3 (es) 2014-05-28 2019-02-11 Univ Dresden Tech Ensayo basado en células y métodos de cribado de moduladores de la señalización de p75NTR

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3236243A1 (de) * 1982-09-30 1984-04-05 Merck Patent Gmbh, 6100 Darmstadt Schwefelhaltige indolderivate
FR2744448B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
BR9810378A (pt) * 1997-07-01 2000-08-29 Novo Nordisk As Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
WO2000059893A1 (en) 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75

Also Published As

Publication number Publication date
EP2310383B1 (fr) 2011-11-30
JP5476372B2 (ja) 2014-04-23
MY151228A (en) 2014-04-30
IL209903A0 (en) 2011-02-28
TW201002686A (en) 2010-01-16
ZA201008791B (en) 2012-02-29
FR2932481B1 (fr) 2010-10-08
FR2932481A1 (fr) 2009-12-18
WO2009150387A1 (fr) 2009-12-17
NZ589842A (en) 2012-12-21
CY1112417T1 (el) 2015-12-09
AU2009259120B2 (en) 2014-01-16
PT2310383E (pt) 2012-03-06
TWI400238B (zh) 2013-07-01
EA019924B1 (ru) 2014-07-30
UY31894A (es) 2010-01-29
MX2010013694A (es) 2011-02-23
BRPI0915482B8 (pt) 2021-05-25
BRPI0915482B1 (pt) 2020-11-24
AU2009259120A1 (en) 2009-12-17
US8247404B2 (en) 2012-08-21
CN102124001A (zh) 2011-07-13
JP2011522868A (ja) 2011-08-04
CN102124001B (zh) 2014-01-22
SI2310383T1 (sl) 2012-03-30
EA201170015A1 (ru) 2011-06-30
RS52252B (en) 2012-10-31
CO6300943A2 (es) 2011-07-21
HRP20120187T1 (hr) 2012-03-31
US20110144122A1 (en) 2011-06-16
PL2310383T3 (pl) 2012-04-30
CA2726666A1 (fr) 2009-12-17
EP2310383B8 (fr) 2012-04-11
DK2310383T3 (da) 2012-03-26
BRPI0915482A2 (pt) 2015-11-10
IL209903A (en) 2014-06-30
CA2726666C (fr) 2016-08-16
KR20110031317A (ko) 2011-03-25
HK1158632A1 (en) 2012-07-20
KR101601999B1 (ko) 2016-03-17
CL2010001432A1 (es) 2011-05-13
ES2378380T3 (es) 2012-04-11
JO2773B1 (en) 2014-03-15
US20120289518A1 (en) 2012-11-15
EP2310383A1 (fr) 2011-04-20
ATE535524T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
AR072102A1 (es) Derivados de 2-oxo-alquil-1-piperazin-2-ona, su preparacion, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por los receptores p75ntr.
AR053344A1 (es) Antagonistas del cgrp,procedimiento para su preparacion,composiciones farmaceuticas que los contienen y usos para el tratamiento de la migrana y otras enfermedades
AR048749A1 (es) 4-(4-trifluorometilpirazolil)-pirimidinas sustituidas
AR062786A1 (es) Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos.
AR061815A1 (es) Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR072224A1 (es) Derivados de pirimidona sustituidos
PE20081372A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE 2-[4-(7-ETIL-5H-PIRROLO[2,3-b]PIRAZIN-6-IL)-FENIL]-PROPAN-2-OL COMO INHIBIDOR DE QUINASA
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
AR062109A1 (es) Derivados sustituidos de espirocetal y uso de los mismos como farmacos terapeuticos para la diabetes. composiciones farmaceuticas.
PE20090312A1 (es) DERIVADO DE 17 -CIANO-18a-HOMO-19-NOR-ANDROST-4-ENO
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR058180A1 (es) Indeno derivados, su preparacion y su uso como medicamentos
AR072227A1 (es) Derivados de triazinona sustituidos
AR077413A1 (es) Derivados piridin-4-ilo
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
UY29893A1 (es) Derivados de pirazina
AR057906A1 (es) Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.
AR053407A1 (es) Derivados de piperazina, proceso para la preparacion de dicho compuesto y composicion farmaceutica que lo comprende.
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
ECSP066304A (es) Compuestos
EA200700997A1 (ru) 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
CO6351789A2 (es) Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos

Legal Events

Date Code Title Description
FG Grant, registration